Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

SOLOPAK PLANS INCLUDE RESTRUCTURING, POSSIBLE IPO following the Nov. 4 cash purchase of the Smith & Nephew subsidiary by the New York investment firm Welsh, Carson, Anderson & Stowe and former Goldline Labs President Otto Nonnenmann. "In addition to expanding the product line" of generic injectables and prefilled syringe products, "increasing the investment in R&D and restructuring the company, long-term plans may include taking the company public," Nonnenmann/WCAS said Nov. 5. Solopak revenues this year are expected to be about $32 mil. Solopak plans to bring in a new upper management level, including a financial officer, a sales and marketing exec and a senior scientist, to perform duties previously handled by Smith & Nephew. The purchase price for Solopak was not disclosed. WCAS purchased about 90% of the firm and Nonnenmann purchased the balance. Under a proposed acquisition announced in March, Ivax was to pay $19 mil. in cash for the company. The deal was called off this summer because "conditions to the consummation of the acquisition were not satisfied," Ivax said ("The Pink Sheet" June 8, In Brief). Nonnenmann is the new president and CEO of Solopak, now renamed Solopak Pharmaceuticals. Welsh, Carson, Anderson & Stowe co-founder Patrick Welsh will be Solopak's chairman. Capitalized at $1.3 bil., WCAS specializes in equity purchases of companies in the health care industry. Solopak's new president moves to the firm from the same position at Goldline Labs. Previous Solopak Acting President Keith Tattersall remains with Smith & Nephew. Nonnenmann's post at Ivax generic distribution drug subsidiary Goldline will be filled by former Goldline VP Bill Schreck. Nonnenmann hopes to continue to be involved with Goldline by reviving a 12-product distribution agreement that was initiated in mid-1991 but never got underway ("The Pink Sheet" June 10, 1991, In Brief). Currently, Solopak has about 120 ANDAs. Prior to joining Goldline as president in 1987, Nonnenmann spent 18 years at Bristol-Myers. From 1983 to 1987, he was CEO of Bristol-Myers GmbH/West Germany. Solopak owns a 92,000 sq. ft. manufacturing facility for generic injectable drugs in Elk Grove, Ill. In Franklin Park, Ill., the company has a 32,000 sq. ft. facility for production of prefilled syringe products. The firm employs over 300 full-time workers. Solopak has been the object of FDA scrutiny recently regarding its manufacturing processes. In August, FDA issued a warning letter to the firm citing deficiencies in good manufacturing practices regulations in its sterile manufacturing operations observed in a March-May inspection ("The Pink Sheet" Sept. 28, T&G-14). FDA's Chicago division is expected to finish an inspection of Solopak's Franklin Park, Ill. facility this week.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts